¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"minimal change disease"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
¿µ¹® rheumatic heart disease ÇÑ±Û ·ù¸¶Æ¼½º½ÉÀ庴
¼³¸í   
  »ç½½¾Ë±Õ°¨¿° ÈÄ »ý±â´Â ½ÉÀåÆÇ¸·º´ÀÌ´Ù. ¿øÀÎÀº A±º -¿ëÇ÷»ç½½¾Ë¿¡ ÀÇÇÑ Àεο°ÈÄ ÀÏÁ¾ÀÇ ¸é¿ª¹ÝÀÀÀ¸·Î ¹ßº´ÇÑ´Ù.
  
  Áø´ÜÀº Á¸ÀÇ ±âÁØ¿¡ ÀÇÇÑ´Ù.
  
  (1) ÁÖ¿ä±âÁØÀº °üÀý¿° ½ÉÀå¿°(½ÉÀåºñ´ë, ½ÉÀåÀâÀ½, ½ÉÀå±â´É»ó½Ç µî) ¹«µµÁõ: ¹«´çÀÌ ÃãÀ» Ãߴ °Í °°Àº ÇൿÀÇ ¹ßÀÛÁõ¼¼. ¿¬º¯È«¹Ý: »¡°£ Å׵θ®¸¦ °¡Áø ÇǺκ´º¯Àº ÇÇÇϰáÀý(subcutaneous nodule): ÇǺΠ¹Ø¿¡ »ý±ä °áÀý,
  
  (2)Âü°í ±âÁØÀº ¿­, °üÀýÅë, EKG»ó PR¿¬Àå: ½ÉÀüµµ ¼Ò°ß ±Þ¼º±â ¹ÝÀÀ¹°Áú(¿¹: ESR, CRP)ÀÇ »ó½Â, ·ù¸¶Æ¼½º¿­
  
  Ä¡·á´Â Æä´Ï½Ç¸°À¸·Î Ä¡·áÇÏ°í ½ÉÀåÀÇ ÈÄÀ¯Áõ ¶ÇÇÑ Æä´Ï½Ç¸°À¸·Î ¿¹¹æÇÑ´Ù.
¿µ¹® chronic obstructive pulmonary disease ÇÑ±Û ¸¸¼ºÆó¼âÆóº´
¼³¸í   
  ¸¸¼ºÀûÀ¸·Î ±âµµÀÇ Æó¼â¸¦ °¡Á®¿À´Â º´À» À̸£´Â ¸». ´ë°³ ¸¸¼º±â°üÁö¿°, ±â°üÁö Ãµ½Ä, Æó±âÁ¾ÀÇ 3°¡Áö º´À» ¸»ÇÑ´Ù.
  
  ¸¸¼º±â°üÁö¿°À̶õ ±â°üÁöÀÇ ¸¸¼º¿°ÁõÀ» ¸»ÇÑ´Ù. ±â°üÁöÀÇ ¿°ÁõÀ¸·Î ÀÎÇØ¼­ ±â°üÁöÀÇ Á¡¸·¿¡ ºÎÁ¾ÀÌ »ý±â°í À̷ΠÀÎÇØ¼­ ±â°üÁöÀÇ ³»°æÀÌ Á¼¾ÆÁ®¼­ ±âµµÀÇ Æó¼â¸¦ °¡Á®¿Â´Ù. ´ë°³ Èí¿¬°ú ¹ÐÁ¢ÇÑ ¿¬°üÀ» °¡Áö¸ç, È£Èí°ï¶õ, ±âħ, ±×¸®°í °¡·¡(´ë°³ »öÀ̠Ǫ¸£°í Á¡µµ°¡ ³ôÀº °¡·¡)°¡ Áõ»óÀ¸·Î ³ªÅ¸³­´Ù.
  
  Æó±âÁ¾Àº ±â°üÁöÀÇ º®À» ÁöÁöÇϴ Á¶Á÷ÀÇ ÆÄ±«¿¡ ÀÇÇØ¼­ ±â°üÁö°¡ Á¦ ¸ð¾çÀ» °®ÃßÁö ¸øÇÏ°í ¹«³ÊÁö°Ô µÇ¾î ±âµµÀÇ Æó¼â°¡ ÀϾ´Â º´ÀÌ´Ù. Áï ±â°üÁö°¡ °ü ¸ð¾çÀ¸·Î ÆØÆØÇϰԠÆìÁö´Â °ÍÀ» ÁöÁöÇϴ Á¶Á÷ÀÇ ÆÄ±«¿¡ ÀÇÇØ¼­ °ü¸ð¾çÀ¸·Î ÆìÁöÁö ¸øÇØ °á±¹Àº ÆóÆ÷³»¿¡ °ø±â°¡ Â÷°í ÆóÆ÷º®ÀÌ ÆÄ¿­µÇ°í ±â°üÁö°¡ Á¼¾ÆÁö°Ô µÇ´Â º´À» ¸»ÇÑ´Ù.
  
  ±â°üÁöõ½ÄÀ̶õ ¿©·¯ °¡Áö Àڱؿ¡ ´ëÇØ¼­ ±â°üÁö°¡ °ú¹ÎÇÑ ¹ÝÀÀÀ» º¸¿©¼­ »ý±â´Â ±â°üÁöÀÇ °¡¿ªÀûÀΠÆó¼â¸¦ ÀǹÌÇÑ´Ù. Áï Á¤»óÀο¡°Ô¼­´Â ±â°üÁöÀÇ Æó¼â¸¦ º¸ÀÌÁö ¾Ê´Â Àڱؿ¡ ´ëÇØ¼­ ±â°üÁöÀÇ Æó¼â°¡ »ý±â°í ±× ÀÚ±ØÀÌ ¾øÀ» °æ¿ì¿¡´Â ±â°üÁöÀÇ Æó¼â°¡ ¾ø¾îÁö´Â º´À» ¸»ÇÑ´Ù. 
¿µ¹® Buerger disease ÇÑ±Û ¹ö°Åº´
¼³¸í   
  ¸»ÃÊ µ¿¸Æ°ú Á¤¸Æ¿¡ ¿°ÁõÀ» ÀÏÀ¸Å°´Â º´. Ã»Àå³âÃþÀÇ ³²ÀÚ¿¡°Ô Àß °É¸®´Â ´Ù¸® µ¿¸Æ¿¡ »ý±â´Â º´À¸·Î µ¿¸ÆÀÌ ¸·È÷°í ÅëÁõ ¶§¹®¿¡ ¹ßÀ» Àý±âµµ Çϴµ¥ ¿øÀÎÀº ¾Ë·ÁÁ® ÀÖÁö ¾Ê´Ù. º´¸íÀº ÀÌ º´À» ÃÖÃʷΠ»ó¼¼ÇϰԠº¸°íÇÑ ¹Ì±¹ÀÇ ÀÇ»ç L. ¹ö°Å(1879~1943)ÀÇ À̸§¿¡¼­ ¿¬À¯ÇÑ´Ù. µ¿¾çÀο¡°Ô ¸¹Àº º´À¸·Î, ´ëºÎºÐ ÀþÀº ³²¼º, Æ¯È÷ Àå³â±â ³²¼º¿¡°Ô¼­ ³ªÅ¸³­´Ù. ¿øÀÎÀº ¾Ë ¼ö ¾øÀ¸³ª Èí¿¬ÀÌ º´ÀÇ ¾ÇÈ­¸¦ ÃÊ·¡ÇÑ´Ù. »çÁöÀÇ µ¿¸Æ°ú Á¤¸Æ¿¡ ¿°ÁõÀÌ ÀϾ Ç÷ÀüÀÌ »ý±â¸é ³»°­À» ¸·¾Æ Ç÷¾×ÀÌ È帣Áö ¸øÇϰԠµÇ¾î ±× ¾ÕÀÇ ¸»ÃÊÁ¶Á÷ÀÌ ±«»ç¿¡ ºüÁö°Å³ª ¼Õ¹ßÀÌ Â÷°©°í, ¼Õ°¡¶ô-¹ß°¡¶ôÀÌ º¸¶ó»ö ¶Ç´Â °ËÀº»öÀ¸·Î º¯ÇÑ´Ù. ¶Ç, ÀÌ Áõ¼¼°¡ °è¼ÓµÇ´Â µ¿¾È ¼Õ¹ß°¡¶ô¿¡ ÅëÁõÀÌ ÀϾ°í ±Ë¾çÀÌ ¹ß»ýÇÑ´Ù. Ä¡·á´Â Áõ¼¼ÀÇ Á¤µµ¿Í Æó»öµÈ Ç÷°üÀÇ ºÎÀ§¿¡ µû¶ó ¿¬°í¸¦ ¹Ù¸£°Å³ª Ç÷°üÈ®ÀåÁ¦-¼øÈ¯°³¼±Á¦-Ç÷¼ÒÆÇÀÀÁý¾ïÁ¦Á¦¸¦ »ç¿ëÇϳª, ¾î¶² Ä¡·áµµ È¿°ú°¡ ¾øÀ» °æ¿ì ¼Õ¹ß°¡¶ôÀÇ ¼ÒÀý´Ü, µå¹°°Ô´Â ¹«¸­ ÀÌÇÏÀÇ ´ëÀý´ÜÀ» ÇؾߠÇÑ´Ù. ÀϹÝÀûÀ¸·Î ÀÌ º´ÀÇ ¿¹ÈĴ ¾çÈ£ÇÏ¿© Ç÷·ù°¡ È¸º¹µÇ°í ±Ë¾ç¸¸ Ä¡·áµÇ¸é Àç¹ßÀÌ Àû´Ù.
¿µ¹® Behcet disease ÇÑ±Û º£Ã¼Æ®º´
¼³¸í   
  ½ÉÇÑ Æ÷µµ¸·¿°, ¸Á¸·Ç÷°ü¿°, ½Ã°¢½Å°æÀ§Ãà, ±¸°­-¼º±âÀÇ ¾ÆÇÁŸ¼º ±Ë¾ç, ±¤¹üÀ§ÇÑ Ç÷°ü¿°ÀǠ¡ÈĿ͠Áõ»óÀ» ³ªÅ¸³½´Ù. ¿øÀκҸíÀÇ Èñ±ÍÇÑ º´À¸·Î ÀþÀº ³²ÀÚ¿¡°Ô Àß ¹ß»ýÇÑ´Ù.
¿µ¹® congenital heart disease ÇÑ±Û ¼±Ãµ½ÉÀ庴
¼³¸í   
  ¼±ÃµÀûÀ¸·Î ½ÉÀåÀÇ ±¸Á¶¿¡ ÀÌ»óÀÌ Àִ º´.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • minimal effective dose
    ÃÖ¼ÒÀ¯È¿·®
  • minimal erythema dose
    ÃÖ¼ÒÈ«¹Ý¼±·®
  • minimal identifiable odor
    ÃÖ¼ÒÀνij¿»õ, ÃÖ¼ÒºÐÇØÃë°¢
  • minimal infecting dose
    ÃÖ¼Ò°¨¿°¿ë·®
  • minimal inhibitory concentration
    ÃÖÀú¾ïÁ¦³óµµ
  • minimal lethal dose
    1. ÃÖ¼ÒÄ¡»ç·® 2. ÃÖ¼ÒÄ¡»ç¼±·®
  • minimal stimulus
    ÃÖ¼ÒÀÚ±Ø
  • minimal tension line
    ÃÖ¼ÒÀå·Â¼±
  • minimal visible angle
    Ãּҽð¢
  • minimal volition period
    ÃÖ¼Ò¼öÃà±â
  • anti-GBM disease
    Ç×GBMº´
  • arteriosclerotic cardiovascular disease
    µ¿¸Æ°æÈ­½É(Àå)Ç÷°üº´
  • arteriosclerotic heart disease
    µ¿¸Æ°æÈ­½ÉÀ庴
  • arthropod-borne viral disease
    ÀýÁöµ¿¹°¸Å°³¹ÙÀÌ·¯½ºº´
  • autoallergic disease
    ÀÚ°¡¾Ë·¹¸£±âº´
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Hashimoto's disease
    ÇϽøðÅ亴
  • Hirschsprung's disease
    (¢¡ congenital megacolon) È÷¸£½´½´ÇÁ·îº´
  • hyaline membrane disease
    À¯¸®Áú¸·º´
  • infectious disease
    °¨¿°º´
  • inflammatory bowel disease
    ¿°ÁõâÀÚÁúȯ
  • inherited disease
    À¯Àüº´
  • Legg-Calve-Perthes disease
    (¢¡ostetochondrosis of the capitualar epiphysis of th) ·¹±×Ä®º£Æä¸£Å×½ºº´, ³Ò´Ù¸®»À¸Ó¸®»À³¡»À¿¬°ñÁõ
  • life style disease
    »ýȰ½À°üº´
  • metabolic disease
    ´ë»çº´, ´ë»çÁúȯ
  • mixed connective tissue disease
    È¥ÇÕ°áÇÕÁ¶Á÷º´
  • moyamoya disease
    ¸ð¾ß¸ð¾ßº´
  • muscle disease
    ±ÙÀ°º´
  • Osgood-Schlatter disease
    (¢¡ osteochondrosis of the tuberosity of the tibia) ¿À½º±Â½¶¶óÅͺ´, Á¤°­»À°ÅÄ£¸é»À¿¬°ñÁõ
  • Paget's disease
    ÆÄÁ¦Æ®º´
  • Parkinson's disease
    ÆÄŲ½¼º´
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • minimal effective dose
    ÃÖ¼ÒÀ¯È¿·®
  • minimal erytherma dose
    ÃÖ¼ÒÈ«¹Ý¼±·®
  • minimal lethal dose
    ÃÖ¼ÒÄ¡»ç·®, ÃÖ¼ÒÄ¡»ç¼±·®
  • minimal enhancement
    ¹Ì¹ÌÇÑÁ¶¿µÁõ°­, °æµµÁ¶¿µÁõ°­
  • minimal current gradient
    ÃÖ¼ÒÀü·ù±â¿ï±â, ÃÖ¼ÒÀü·ù°æ»ç
  • minimal tension line
    ÃÖ¼ÒÀå·Â¼±
  • minimal stimulus
    ÃÖ¼ÒÀÚ±Ø
  • minimal angle resolution
    ÃÖ¼Ò°¢ºÐÇØ´É
  • minimal daily requirement
    ÃÖ¼Ò¿µ¾çÇʿ䷮, ÃÖ¼ÒÀÏÀϿ䱸·®
  • minimal identifiable odor
    ÃÖ¼ÒºÐÇØÃë°¢, ÃÖ¼ÒÀνij¿»õ
  • minimal nerve excitability test
    ÃּҽŰæÀڱذ˻ç
  • minimal stimulating test
    ¹Ì¾àÁÖÀÔÀڱؽÃÇè
  • minimal volition period
    ÃÖ¼Ò¼öÃà±â
  • accumulation disease
    ÃàÀûº´
  • acquired cystic kidney disease
    ÈÄõ³¶¼ºÄáÆÏº´
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Alzheimer disease
    ¾ËÂêÇÏÀÌ¸Ó Áúȯ
  • Alzheimer s disease
    ¾ËÂêÇÏÀ̸Ӻ´.
  • Alzheimers disease
    ¾ËÂêÇÏÀ̸Ӻ´.
  • American hookworm disease
    ¾Æ¸Þ¸®Ä«±¸Ã溴.
  • Aujeszkys disease virus
    ¿ÀÁ¦½ºÅ°º´¹ÙÀÌ·¯½º
  • B rgers disease
    ¹ö°Åº´.
  • Balos disease
    ¹ß·Îº´.
  • Bantis disease
    ¹ÝƼº´ ¡ì°£Á¾Ã¢¼º ºñÁ¾¡í.
  • Beards disease
    º£¾îµåº´=¼è¾àÁõÈıº(neurasthenia)
  • Beh ets disease
    º£Ã¼Æ®º´
  • Behcets disease
    º£¼¼Æ®º´
  • Behrs disease
    º£¸£º´
  • Bernard-Soulier disease
    º£¸£³ª¸£-¼ú¸®¿¡Áúȯ<--º´> ?
  • Bournevilles disease->tuberous sclerosis
    ºÎ¸£³×ºôº´
  • Bowens disease
    º¸À¢ º´
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • phasic change
    À§»ó¼º º¯È­(êÈßÓàõܨûù).
  • physical change
    ¹°¸®º¯È­(ÚªìµÜ¨ûù).
  • rachitic change
    ±¸·ç¼º º¯È­( ×§àõܨûù).
  • rachitic change
    ±¸·ç¼º º¯È­(±¸×§àõܨûù)
  • retinal change of hypertension
    °íÇ÷¾ÐÀÇ ¸Á¸·º¯È­.
  • retinal change of hypertension
    °íÇ÷¾ÐÀÇ ¸Á¸·º¯È­(ÍÔúìäâ¡­¡­Ü¨ûù)
  • reversible change
    °¡¿ªº¯È­(ʦæ½Ü¨ûù).
  • time zone change(jet lag) syndrome
    ½ÃÂ÷ ÁõÈıº(ãÁó¬ñøý¦ÏØ).
  • minimal air
    ÃÖ¼Ò°ø±â.
  • minimal angle resolution
    ÃÖ¼Ò°¢ºÐÇØ´É.
  • minimal auditory threshold
    ÃÖ¼Ò°¡Ã»¿ªÄ¡(õÌ á³Ê¦ôéÚÊö·).
  • minimal auditory threshold
    ÃÖ¼Ò°¡Ã»¿ªÄ¡
  • minimal bactericidal concentration (MBC)
    »ì±ÕÃÖ¼Ò³óµµ
  • minimal blood pressure
    ÃÖ¼ÒÇ÷¾Ð.
  • minimal brain dysfunction
    °æ¹Ì³ú±â´ÉÀå¾Ö.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Christmas disease
    Å©¸®½º¸¶½ºÁúȯ(òðü´)
  • Cori's disease
    ÄÚ¸® Áúȯ(òðü´) (ÔÒ) glycogen storage disease type III
  • Cushing's disease
    Äí½Ì Áúȯ(òðü´)
  • cytogenetic disease
    ¼¼Æ÷À¯ÀüÁúȯ(á¬øàë¶îîòðü´)
  • deficiency disease
    °áÇÌ Áúȯ(ÌÀù¹òðü´)
  • Fabry's disease
    ÆÄºê¸® Áúȯ (òðü´)
  • Farber's disease
    ÆÄ¾Æ¹ö Áúȯ(òðü´)
  • Forbe`s disease
    Æ÷ºê Áúȯ(òðü´)
  • Gaucher's disease
    °í¿À¼Å Áúȯ(òðü´)
  • genetic disease
    À¯Àü Áúȯ(ë¶îîòðü´)
  • Gilbert's disease
    ±æ¹öÆ® Áúȯ(òðü´)
  • glycogen storage disease
    ±Û¶óÀÌÄÚÀü ÀúÀå Áúȯ(îÍíúòðü´)
  • Hartnup's disease
    ÇÏÆ®³Ò Áúȯ(òðü´)
  • heavy-chain disease
    Áß(ñì)»ç½½ Áúȯ(òðü´)
  • Hers' disease
    ¿¡¸£½º Áúȯ(òðü´)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • communicable disease
    Àü¿°º´
  • constitutional disease
    üÁú¼ºÁúȯ
  • coronary heart disease
    °ü»óµ¿¸Æ½ÉÁúȯ
  • Crohn's disease
    Å©·Ðº´
  • Crouzon's disease
    µÎ°³¾È¸éȸ°ñºÎÀüÁõ, Å©·çÁ¸º´
  • cyanotic heart disease
    û»ö¼º½ÉÀåÁúȯ
  • degenerative joint disease
    ÅðÇ༺°üÀýÁúȯ
  • demyelinating disease
    Å»¼öÃʼºÁúȯ
  • disease
    º´, Áúº´, Áúȯ
  • endemic disease
    Áö¹æº´, dzÅ亴
  • endocrine disease
    ³»ºÐºñÁúȯ
  • focal disease
    ÃÊÁ¡¼ºÁúȯ
  • glycogen storage disease
    ±Û¸®ÄÚ°Õ ÃàÀûÁúȯ
  • granulomatous disease
    À°¾ÆÁ¾¼ºÁúȯ
  • Hand-Schueller-Christian disease
    ÇÚµå-½¯·¯-Å©¸®½ºÂùº´
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
MBD Marchiafava-Bignami disease; Mental Deterioration Battery; methylene blue dye; minimal brain damage;...
MCD   1) Minimal Change Disease
  2) Menstrual Cycle Day
MCL Minimal Change Disease
AD accident dispensary; acetate dialysis; active disease; acute dermatomyositis; addict, addiction; ade...
PD Doctor of Pharmacy; Dublin Pharmacopoeia; interpupillary distance; Paget disease; pancreatic duct; p...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
FAC Fractional area change
HSC Health System Change
NC No Change
EMEM Eagle's Minimal Essential Medium
MAS Minimal Access Surgery
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • compensatory change
    ´ë»ó¼º º¯È­
  • dental change
    Ä¡¾Æ º¯È­
  • dysplastic change
    ÀÌÇü¼º º¯È­
  • erosive mucosal change
    ¹Ì¶õ¼º Á¡¸· º¯È­
  • erosive-atrophic mucosal change
    ¹Ì¶õ À§Ã༺ Á¡¸· º¯È­
  • eye change
    ¾È º¯È­
  • frequency change
    ÁÖÆÄ ¼ö º¯È­
  • hyperkeratotic change
    °ú°¢È­¼º º¯È­
  • hyperplastic change
    Áõ½Ä¼º º¯È­
  • hypotrophic change
    À§Ãà º¯È­
  • inflammatory change
    ¿°Áõ º¯È­, ¿°Áõ¼º º¯È­
  • large nodular change
    °Å´ë °áÀý º¯È­
  • lifestyle change
    »ýȰ ¾ç½ÄÀÇ º¯È­
  • macular change
    ¹ÝÁ¡¼º º¯È­
  • mucosal change
    Á¡¸· º¯È­
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
minimal air The volume of gas that remains in the lungs and cannot be expelled after they have been removed from the body, or after the chest has been opened.
(05 Mar 2000)
minimal alveolar concentration The end-alveolar concentration of an inhalation anaesthetic which prevents somatic response to a painful stimulus in 50% of individuals; an index of relative potency of inhalation anaesthetics.
Synonym: minimal anaesthetic concentration.
(05 Mar 2000)
minimal amplitude nystagmus Nystagmus of so small an amplitude that it is not detected by the usual clinical tests.
Synonym: minimal amplitude nystagmus.
Origin: micro-+ G. Nystagmos, a nodding
(05 Mar 2000)
minimal anaesthetic concentration The end-alveolar concentration of an inhalation anaesthetic which prevents somatic response to a painful stimulus in 50% of individuals; an index of relative potency of inhalation anaesthetics.
Synonym: minimal anaesthetic concentration.
(05 Mar 2000)
minimal brain dysfunction An inability to control behaviour due to difficulty in processing neural stimuli.
(12 Dec 1998)
minimal deviation melanoma <dermatology, tumour> A malignant melanoma showing less cytologic atypia than is usual in melanoma cells showing asymmetric expansile invasion of the dermis.
(05 Mar 2000)
minimal dose <pharmacology> The smallest amount of a drug or physical procedure that will produce a desired physiologic effect in an adult.
(05 Mar 2000)
minimal infecting dose <microbiology> The smallest quantity of infectious material regularly producing infection; usually expressed as I.D.50, the quantity causing infection in 50% of a suitable series of animals or cells (cell cultures).
(05 Mar 2000)
minimal inhibitory concentration <microbiology, pharmacology> The lowest concentration of antibiotic sufficient to inhibit bacterial growth when tested in vitro.
(05 Mar 2000)
minimal lethal dose <pharmacology> The minimal dose of a toxic substance or infectious agent that is lethal, as assayed in various experimental animals (e.g., the least amount of diphtheria toxin that, on an average, kills a 250-g guinea pig within 96 hours after subcutaneous inoculation).
When followed by a subscript (generally "MLD50"), denotes the minimal dose that is lethal to a certain percentage (e.g., 50%) of animals so assayed, LD05.
See: lethal dose.
(05 Mar 2000)
minimal medium <cell culture> The simplest tissue culture medium that will support the proliferation of normal cells.
(18 Nov 1997)
minimal reacting dose The minimal dose of a toxic substance causing a reaction, as manifested in the skin of a series of susceptible test animals; the assay is based on the development of a characteristic, minimal but definite, "standard," focal inflammation (congestion and oedema, induration, degenerative changes, and desquamation of epidermal cells).
(05 Mar 2000)
aaa disease Endemic anaemia of ancient Egypt, ascribed in the Papyrus Ebers to intestinal infestation with ancylostoma; now called ancylostomiasis.
(05 Mar 2000)
ABO haemolytic disease of the newborn Erythroblastosis foetalis due to maternal-foetal incompatibility with respect to an antigen of the ABO blood group; the foetus possesses A or B antigen which is lacking in the mother, and the mother produces immune antibody which causes haemolysis of foetal erythrocytes.
(05 Mar 2000)
accumulation disease A disease characterised by abnormal accumulation of a metabolic product in certain cells and tissues; examples include the mucopolysaccharidoses, lipoidoses.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • change-up
    üÀÎÁö¾÷(ŸÀÚÀÇ Å¸À̹ÖÀ» ¾î±ß³ª°Ô Çϱâ À§ÇØ ¼Ó±¸ °°Àº ¸ð¼ÇÀ¸·Î ´øÁö´Â ¿Ï±¸)
  • functional change
    ±â´É Àüȯ
  • gear change
    (ƯÈ÷ ÀÚµ¿Â÷ÀÇ)º¯¼Ó·¹¹ö;±â¾î Àüȯ ÀåÄ¡
  • grammatical change
    ¹®¹ýÀû º¯È­;º£¸£³ÊÀÇ ¹ýÄ¢
  • sea change
    ¹Ù´Ù(Á¶¼ö)¿¡ ÀÇÇÑ º¯È­;º¯È­;º¯¸ð
  • small change
    Àܵ·;½Ã½ÃÇÑ À̾߱â
  • disease
    º´,Áúȯ
  • Creutzfeldt-Jakob disease
    Å©·ÎÀÌÃ÷ÆçÆ®¾ßÄߺ´
  • DUST DISEASE
    =PNEUNOCONIOSIS
  • Dutch elm disease
    (½Ä)¼¼±Õ¼ºÀÇ ´À¸¨³ª¹«º´
  • English disease
    ¿µ±¹º´(³ëµ¿ÀÚÀÇ Å¾÷¿¡ ÀÇÇÑ »ý»ê ÀúÇÏ µîÀÇ »çȸÀû º´Æó);(°í)±¸·çº´;±â°üÁö¿°
  • Fabry's disease
    ÆÄºê¸®º´(¼±Ãµ¼º ÁöÁú ´ë»ç ÀÌ»óÁõ)
  • GVH disease
    ´ë¼÷ÁÖ¼º ÀÌ½ÄÆíº´
  • Graves' disease
    ±×·¹À̺êÁî(¹ÙÁ¦µµ)º´
  • Hansens disease
    ÇѼ¾º´;¹®µÕº´
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á